David Pelizzon Sells 326,700 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 326,700 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the sale, the director owned 6,536,764 shares of the company’s stock, valued at $150,607,042.56. This trade represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

OrthoPediatrics Trading Down 0.9%

Shares of NASDAQ:KIDS opened at $22.80 on Thursday. OrthoPediatrics Corp. has a 12-month low of $14.42 and a 12-month high of $26.74. The business has a 50 day moving average of $21.68 and a 200-day moving average of $18.80. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The stock has a market cap of $595.31 million, a PE ratio of -13.57 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, equities research analysts forecast that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its stake in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares in the last quarter. Legal & General Group Plc acquired a new stake in OrthoPediatrics during the second quarter worth about $34,000. Northwestern Mutual Wealth Management Co. raised its position in shares of OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after buying an additional 2,561 shares in the last quarter. Caption Management LLC acquired a new position in shares of OrthoPediatrics in the 3rd quarter valued at approximately $54,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the period. Institutional investors own 69.05% of the company’s stock.

Key OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Wall Street’s consensus rating remains Moderate Buy, with an average price target of $26.44. Piper Sandler maintained an Overweight rating and raised its target to $25, while Needham increased its target to $35 and reiterated Buy. OrthoPediatrics analyst coverage
• Positive Sentiment: Several institutions increased their positions during the first half of the year. Millennium Management raised its stake by 55.3%, Goldman Sachs more than doubled its holdings, and institutional investors collectively own approximately 69.05% of outstanding shares.
• Positive Sentiment: OrthoPediatrics recently exceeded quarterly expectations, reporting revenue of $70.51 million versus the $68.21 million consensus estimate and a loss of $0.26 per share, better than the expected $0.30 loss. This suggests operating results are progressing ahead of forecasts, despite the company remaining unprofitable.
• Neutral Sentiment: The reported transactions appear in multiple director, major-shareholder and beneficial-ownership filings, so some disclosures may represent overlapping ownership records rather than separate sales. The reporting holders still controlled roughly 6.53 million shares after the transactions. SEC ownership filing
• Negative Sentiment: Director David Pelizzon and major shareholder Jennifer N. Pritzker reported sales totaling 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. The sales reduced reported ownership by 4.76% and may weigh on sentiment by creating an insider-selling overhang.
• Negative Sentiment: The same ownership group also reported sales of 10,131 shares on September 1 at $23.10, valued at about $234,000 per filing. While the 0.15% reduction is modest, the additional selling reinforces the near-term supply concern. OrthoPediatrics insider sale report

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KIDS. Needham & Company LLC boosted their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. BTIG Research boosted their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Finally, Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and an average target price of $26.44.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.